Novo Nordisk's Wegovy Pill Hits 217,050 Weekly Scripts as 26 Abstracts Loom for Washington
Published on 11/01/2026 at 19:21 | Editorial boerse-global.de
Novo Nordisk's oral Wegovy has set a fresh US high for weekly prescriptions, with the latest reporting week showing a 4.2% climb to 217,050 — the strongest reading since the tablet reached the market. The figure, carried in media reports on Friday, offers a concrete demand signal at a time when the company's pipeline narrative is doing much of the talking.
Shares advanced 2.7% on Friday, yet neither source of positive news can be tied to that move with any confidence. The prescription record and the day's gain sit side by side without a proven causal link, and the same caution applies to the research calendar the company has just laid out.
A Prescription Record, Not a Revenue Line
What the 217,050 figure measures is uptake, not economics. Prescription counts track demand and should not be read as a sales or earnings disclosure. The record therefore gives investors an operational marker while leaving the broader question of Novo Nordisk's financial trajectory unanswered.
Competitive pressure supplies the counterweight. Reuters reported on Friday that Eli Lilly is widening its lead over Novo Nordisk in GLP-1 medicines, a picture reinforced by Lilly's quarterly report and its raised 2026 revenue guidance. No direct link between that coverage and Novo Nordisk's Friday share move can be established either.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The two developments are not mutually exclusive. The Wegovy pill can keep setting prescription highs while a rival builds out its position — which is why the distinction between progress on a single product and the company's relative standing matters. Stronger use of the tablet does not refute the competitive pressure Reuters described.
What Washington Will and Won't Deliver
Novo Nordisk said on Thursday it will present 26 abstracts on its obesity portfolio at ObesityWeek, running from 14 to 17 November in Washington, D.C. The programme spans CagriSema analyses, Wegovy data drawn from real-world treatment and research into paediatric obesity. Experiences with the Wegovy pill outside controlled trials are also on the agenda — observations that complement clinical research with everyday practice but must be distinguished from pre-specified study conditions. No additional therapeutic benefit can be inferred from the announcement itself.
A separate set of twelve abstracts is headed for The Liver Meeting, scheduled for 5 to 9 November, covering clinical and care-adjacent semaglutide data alongside contributions on the investigational drug Efruxifermin. The announcements were made on different days — the liver programme on Wednesday, the obesity slate on Thursday — and neither contains new efficacy results.
Reading CagriSema With Care
The one hard number on the CagriSema file comes from a post-hoc analysis of the REDEFINE 1 trial, published on 20 October. Novo Nordisk reported an average weight loss of 25.0% after 68 weeks among women who stayed on treatment, against 3.0% in the placebo arm.
Context is essential here. The analysis was not a prospectively designed study of differing menopause stages, so the finding cannot be read as a general treatment result without those qualifications. The CagriSema readouts still to come should be judged on more than the size of a reported weight reduction: the patient group examined, the comparator and whether an analysis was planned in advance all carry equal weight.
For investors, the dividing line runs between statements grounded in controlled trials and supplementary evaluations layered on afterwards. The volume of presentations matters less than their evidentiary strength, and the next durable step forward would not be a presentation as such but a clearly demonstrated additional benefit. Until then, the prescription record stands as the concrete positive datapoint, with the November calendar set to extend the news flow without pre-empting it.
Ad
Novo Nordisk Stock: New Analysis - 1 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
